On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of kansarka sanbabada conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes buro cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb ayaa shaaca ka qaaday in shirkaddu ay u gudbisay codsiga Opdivo ee daawaynta calaamadaha kansarka sanbabada FDA iyo maamulka dawooyinka ee EU. Dabcan, Shirkadda Squibb ee hamiga leh dabiici ahaan kuma qanacsana oo keliya kansarka sanbabada iyo melanoma. Dhab ahaantii, Squibb wuxuu hadda wadaa in ka badan 35 daraasadood oo Opdivo ah oo keliya ama lagu daro daawooyinka kale si loo daaweeyo noocyada kala duwan ee burooyinka. Sida laga soo xigtay falanqeeyayaasha, iibka mustaqbalka ee Opdivo wuxuu gaari doonaa ilaa 5 bilyan oo doolarka Mareykanka ah.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Warbixin English oo faahfaahsan:
Bristol-Myers Squibb's ($ Cur) ee u taagan tallaalka immuno-o ncology nivolumab, oo la ansixiyay bishii la soo dhaafay sida Opdivo, ayaa dhaliyay guul la taaban karo oo laga gaaray tijaabada kansarka sambabada ee marxaladda dambe, taasoo xoojinaysa rajada iibka ee daawaynta pio neering.
Daraasad 272-bukaan ah oo Opdivo ka soo horjeeda docetaxel-ka-killer-ka caadiga ah, Bristol-Myers daroogadu waxay muujisay badbaadada guud ee heer sare ah marka la barbar dhigo cududda kontoroolka oo ay ku dhufatay barta ugu dambeysa ee jadwalka ka hor, taasoo hogaamineysa xogta tijaabada ee guddiga daraasadda waa in la joojiyo goor hore. Bristol-Myers waxay hadda ku martiqaadaysaa bukaanada kooxda docetaxel si ay u doortaan Opdivo iyada oo loo marayo daraasad summadeed oo furan.
Daawaynta Bristol-Myers waxaa loogu talagalay in lagu galvanize habka difaaca jirka ee burooyinka iyadoo la xirayo dariiqa loo yaqaan PD-1, taas oo, aan la xakameynin, u oggolaanaysa unugyada kansarka inay gudbaan iyada oo aan la ogaanin difaaca dabiiciga ah ee jirka. Sida Merck's ($ MRK) Keytruda la mid ah, Opdivo wuxuu ku guuleystey oggolaanshaha FDA sannadkii hore sidii daawaynta melanoma, laakiin dawada Bristol-Myers waxay kaligeed ku taagan tahay kansarka sanbabada, iyadoo guusheedii caafimaad ee ugu dambeysay ay calaamad u tahay markii ugu horeysay ee PD-1 inhibitor ah uu soo saaro faa'iidada badbaadada ee cudurka, shirkaddu waxay tiri.
Opdivo’s particular promise in kansarka sanbabada ee aan yareyn has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers waxay u gudbisay codsiyada kansarka sanbabada ee Maraykanka iyo Yurub ee Opdivo ee kansarka sanbabada, iyadoo la filayo inay ballaariso isticmaalka dawada dabayaaqada sanadkan.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, kansarka madaxa iyo qoorta, glioblastoma, Non-Hodgkin lymphoma and other cancers.
